Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Malaria Vaccines Market Growth Potential: How Will Market Size Change Through 2030?

The global market for malaria vaccines has experienced remarkable expansion lately. Projections indicate a significant increase, moving from $6.24 billion in 2025 to $8.36 billion in 2026, reflecting a robust compound annual growth rate of 33.9%. This surge in growth during the preceding period can be attributed to several key factors: the substantial prevalence of malaria in areas where it is endemic, persistent worldwide efforts aimed at eradicating the disease, financial backing provided by international health organizations, the growing challenge posed by resistance to antimalarial drugs, and the promising early outcomes observed with the initial generation of malaria vaccines.

The global market for malaria vaccines is projected for substantial expansion in the coming years, reaching an estimated $27.18 billion by 2030 with a compound annual growth rate (CAGR) of 34.3%. This projected surge is fueled by several key factors, including heightened government investment in preventing infectious diseases, the geographical spread of malaria-prone areas due to climate change, a greater need for vaccines that provide sustained immunity, progress in vaccine development and testing, and broader vaccination initiatives in economically disadvantaged nations. Over the forecast period, significant trends are anticipated to shape the market, such as the introduction of advanced malaria vaccines, an increased focus on immunizing children, enhanced collaborations between public and private entities for vaccine distribution, a growing preference for vaccines targeting multiple antigens or in combination, and intensified efforts to conduct widespread vaccination drives in regions where malaria is prevalent.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13698&type=smp

Malaria Vaccines Market Opportunity Drivers: What Is Creating New Revenue Potential?

The increasing prevalence of illnesses transmitted by mosquitoes is anticipated to be a key driver for the expansion of the malaria vaccine market. These mosquito-borne diseases encompass a wide spectrum of health conditions transmitted through the bite of infected mosquitoes. Specifically, the malaria vaccine, such as the RTS, S/AS01 (RTS, S) formulation, plays a crucial role in averting and mitigating the effects of these infectious diseases by preparing the body’s immune system to identify and combat the malaria parasite. As an illustration, data from the UK Health Security Agency (UKHSA), a governmental body in the United Kingdom, revealed in December 2024 that the UK recorded 2,106 instances of imported malaria in 2023, marking a 26% increase compared to the figures from 2022. Consequently, the upward trend in mosquito-related disease occurrences is directly fueling the growth trajectory of the malaria vaccine market.

Malaria Vaccines Market Segment Analysis: What Are The Major Market Categories?

The malaria vaccines market covered in this report is segmented –

1) By Agent: Plasmodium Falciparum, Plasmodium Vivax

2) By Vaccine Type: Pre-Erythrocytic, Erythrocytic, Multi-antigen, Other Vaccines

3) By Route Of Administration: Intramuscular, Subcutaneous, Intradermal, Other Routes Of Administration

4) By Distribution Channel: Public, Private

Subsegments:

1) By Plasmodium Falciparum: RTS,S/AS01 Vaccine, Experimental Vaccines

2) By Plasmodium Vivax: Candidate Vaccines In Development, Combination Vaccines

Malaria Vaccines Market Innovation Trends Driving Future Development

Leading players within the malaria vaccine sector are prioritizing the creation of groundbreaking treatments, specifically next-generation recombinant vaccines, to address the escalating need fueled by growing malaria incidence, governmental backing, and the broadening of vaccination initiatives. These advanced recombinant vaccines employ sophisticated genetic modification methods to target diverse phases of the malaria parasite’s life cycle, thereby eliciting stronger immune reactions and offering more enduring protection than conventional vaccines, which typically target a solitary phase and deliver restricted effectiveness. To illustrate, in October 2025, Zambia’s government initiated the rollout of the R21/Matrix-M malaria vaccine, integrating it into its comprehensive immunization schedule. This vaccine, a product of joint efforts by the University of Oxford and the Serum Institute of India, utilizes a recombinant protein approach coupled with the Matrix-M adjuvant to amplify the immune system’s response; it is administered through a four-dose regimen commencing at six months of age and is intended to supplement current malaria prevention strategies. With superior effectiveness, it aims to safeguard children in Zambian regions experiencing high and moderate malaria transmission, playing a crucial role in the broader objective of eradicating malaria.

Malaria Vaccines Market Leading Companies Driving Competitive Growth

Major companies operating in the malaria vaccines market are GlaxoSmithKline Plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Sanaria Inc, BioNTech SE, Moderna Inc, Pfizer Inc, Novavax Inc, Takeda Pharmaceutical Company Limited, Sanofi SA, Zydus Lifesciences Limited, Valneva SE, GeoVax Labs Inc, Inovio Pharmaceuticals Inc, Vaxart Inc, CanSino Biologics Inc, Sinovac Biotech Ltd, Clover Biopharmaceuticals Inc, Biological E Limited, Emergent BioSolutions Inc

Access The Complete Malaria Vaccines Market Report:

https://www.thebusinessresearchcompany.com/report/malaria-vaccines-global-market-report

Malaria Vaccines Market Global Footprint: Which Region Holds Market Leadership?

North Americawas the largest region in the malaria vaccines market in 2025. Asia-Pacificis expected to be the fastest growing region in the forecast period. The regions covered in the malaria vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model